author-photo

Maureen Hattersley

AstraZeneca

32

Papers

661

Citations

Citation Trend

Filter By

Papers (20) Sort By

Journal Conference Others

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status

2021 Journal of Hematology & Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3 mimetic resistance in lymphomas.

2020 Blood
Show All
- Source
- Cite
- Save
Citations (5)
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children

2020 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (8)
Modelling dose and schedule effects of AZD2811 nanoparticles targeting aurora kinase B for treatment of diffuse large B-cell lymphoma

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (5)
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency

2018 Cancer Cell
Show All
- Source
- Cite
- Save
Citations (126)
BRD4 facilitates replication stress-induced DNA damage response

2018 Oncogene
Show All
- Source
- Cite
- Save
Citations (39)
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors

2018 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (24)
Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (11)
Abstract 1026: Identify BRD4 as a facilitator of replication stress response signaling

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)